drugset / Trial / NCT00170742

Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

NCT00170742

Phase 3 Terminated 17 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.

Timeline

Start
2003-12
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 30 mg Intramuscular